AR047531A1 - Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa - Google Patents
Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasaInfo
- Publication number
- AR047531A1 AR047531A1 ARP050100399A ARP050100399A AR047531A1 AR 047531 A1 AR047531 A1 AR 047531A1 AR P050100399 A ARP050100399 A AR P050100399A AR P050100399 A ARP050100399 A AR P050100399A AR 047531 A1 AR047531 A1 AR 047531A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- branched
- linear
- hydrogen atom
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Proceso para su preparacion y composiciones farmacéuticas que los comprenden; los compuestos pueden ser utiles en terapia, en el tratamiento de enfermedades asociadas con una mala regulacion de la actividad proteína quinasa, como cáncer. Reivindicacion 1: Un compuesto de formula (1), caracterizado porque: R es un grupo arilo o heteroarilo opcionalmente sustituido; R1 y R2 son el mismo o son diferente, y representan independientemente entre sí, un átomo de hidrogeno, un alquilo C1-3 lineal o ramificado o un grupo -CONH2 o -CH2NR'R'' o, tomados juntos con el átomo de carbono al que están unidos, R1 y R2 pueden formar un grupo cicloalquilo C3-6; siempre y cuando por lo menos uno de R1 y R2 sea diferente de un átomo de hidrogeno; R' y R'' son el mismo o diferentes, y representan independientemente entre sí, un átomo de hidrogeno o un grupo alquilo C1-3 lineal o ramificado o, tomados junto con el átomo de nitrogeno al que están unidos, R' y R'' pueden formar un anillo heterocíclico del resto de grupo de formula (2), donde R''' es un átomo de hidrogeno o un grupo alquilo C1-3 lineal o ramificado; R3 es un átomo de hidrogeno o halogeno o un grupo que se selecciona entre hidroxi, ciano, alquilo C1-3 lineal o ramificado o alcoxi C1-3; o isomeros, tautomeros, vehículos, metabolitos, prodrogas, y sales de los mismos aceptables para uso farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54145204P | 2004-02-03 | 2004-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047531A1 true AR047531A1 (es) | 2006-01-25 |
Family
ID=34837492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100399A AR047531A1 (es) | 2004-02-03 | 2005-02-02 | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8138217B2 (es) |
| EP (1) | EP1711177B1 (es) |
| JP (1) | JP4908233B2 (es) |
| KR (1) | KR20060124734A (es) |
| CN (1) | CN1946395B (es) |
| AP (1) | AP2006003701A0 (es) |
| AR (1) | AR047531A1 (es) |
| AT (1) | ATE396724T1 (es) |
| AU (1) | AU2005210114B2 (es) |
| BR (1) | BRPI0507375A (es) |
| CA (1) | CA2555262C (es) |
| CR (1) | CR8546A (es) |
| CY (1) | CY1108246T1 (es) |
| DE (1) | DE602005007181D1 (es) |
| DK (1) | DK1711177T3 (es) |
| DO (1) | DOP2005000014A (es) |
| EA (1) | EA011032B1 (es) |
| EC (1) | ECSP066767A (es) |
| ES (1) | ES2307144T3 (es) |
| GE (1) | GEP20094633B (es) |
| GT (1) | GT200500020A (es) |
| HK (1) | HK1101343A1 (es) |
| IL (1) | IL177141A0 (es) |
| MA (1) | MA28429B1 (es) |
| MX (1) | MXPA06008787A (es) |
| NO (1) | NO20063768L (es) |
| NZ (1) | NZ548896A (es) |
| PA (1) | PA8622801A1 (es) |
| PE (1) | PE20051095A1 (es) |
| PL (1) | PL1711177T3 (es) |
| PT (1) | PT1711177E (es) |
| SI (1) | SI1711177T1 (es) |
| TN (1) | TNSN06244A1 (es) |
| TW (1) | TW200526204A (es) |
| UA (1) | UA86223C2 (es) |
| UY (1) | UY28738A1 (es) |
| WO (1) | WO2005074922A1 (es) |
| ZA (1) | ZA200606179B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0312961A (pt) * | 2002-07-25 | 2005-06-14 | Pharmacia Italia Spa | Derivados condensados heterociclicos de pirazol como inibidores de cinase |
| ES2439918T3 (es) | 2005-07-19 | 2014-01-27 | Nerviano Medical Sciences S.R.L. | Compuestos de 1H-tieno[2,3-c]-pirazol útiles como inhibidores de cinasas |
| CA2624795A1 (en) * | 2005-10-06 | 2007-04-12 | Merck Sharp & Dohme Limited | Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as d-amino acid oxidase inhibitors |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP2009534307A (ja) * | 2006-03-30 | 2009-09-24 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 特定の耐性腫瘍の治療のためのキナーゼ阻害剤の使用 |
| US8119641B2 (en) | 2006-05-31 | 2012-02-21 | Nerviano Medical Sciences S.R.L. | 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors |
| FR2904626B1 (fr) * | 2006-08-03 | 2008-09-19 | Sanofi Aventis | Derives de pyrazolo[4,3]thiazole, leur preparation et leur application en therapeutique |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| KR100923540B1 (ko) | 2007-11-23 | 2009-10-27 | 한국과학기술연구원 | 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법 |
| AR071780A1 (es) * | 2008-05-15 | 2010-07-14 | Nerviano Medical Sciences Srl | Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos |
| CA2755768A1 (en) | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| US9255072B2 (en) | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| US9527863B2 (en) * | 2012-04-05 | 2016-12-27 | Nerviano Medical Sciences S.R.L. | Thieno-indole moieties and methods of treating using the same |
| WO2019024809A1 (zh) * | 2017-08-01 | 2019-02-07 | 正大天晴药业集团股份有限公司 | 作为RORγ抑制剂的双环化合物 |
| TWI803541B (zh) * | 2017-11-30 | 2023-06-01 | 韓商韓美藥品股份有限公司 | 對於蛋白激酶具抑制活性之噻吩并[3,2-d]嘧啶化合物 |
| CN113072562B (zh) * | 2021-04-06 | 2022-01-14 | 山东大学 | 一种GSK-3β抑制剂及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2015566B3 (es) | 1986-02-19 | 1990-09-01 | Duphar Int Res B V | Nuevos compuestos tio que tienen actividad fungicida. |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| EE200200065A (et) | 1999-08-12 | 2003-04-15 | Pharmacia Italia S.P.A. | 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon |
| US7541354B2 (en) * | 2000-08-10 | 2009-06-02 | Pfizer Italia S.R.L. | Bicyclo-pyrazoles |
| AU2002215053A1 (en) | 2000-11-27 | 2002-06-24 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| EP1379524A2 (en) | 2001-01-26 | 2004-01-14 | Pharmacia Italia S.p.A. | Chromane derivatives, process for their preparation and their use as antitumor agents |
| CA2460145C (en) | 2001-09-26 | 2011-04-26 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| ES2411655T3 (es) * | 2002-05-17 | 2013-07-08 | Pfizer Italia S.R.L. | Derivados de aminoindazol activos como inhibidores de quinasas, procedimiento para su preparación y composiciones farmacéuticas que los comprenden |
| ATE393159T1 (de) * | 2002-07-17 | 2008-05-15 | Pfizer Italia Srl | Heterobicyclische pyrazolderivate als kinaseinhibitoren |
| BR0312961A (pt) * | 2002-07-25 | 2005-06-14 | Pharmacia Italia Spa | Derivados condensados heterociclicos de pirazol como inibidores de cinase |
| US20050026984A1 (en) * | 2003-07-29 | 2005-02-03 | Aventis Pharma S.A. | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products |
-
2005
- 2005-01-28 TW TW094102761A patent/TW200526204A/zh unknown
- 2005-02-02 DE DE602005007181T patent/DE602005007181D1/de not_active Expired - Lifetime
- 2005-02-02 CN CN200580005922.0A patent/CN1946395B/zh not_active Expired - Fee Related
- 2005-02-02 PT PT05701307T patent/PT1711177E/pt unknown
- 2005-02-02 DK DK05701307T patent/DK1711177T3/da active
- 2005-02-02 AT AT05701307T patent/ATE396724T1/de active
- 2005-02-02 PE PE2005000121A patent/PE20051095A1/es not_active Application Discontinuation
- 2005-02-02 UA UAA200609515A patent/UA86223C2/uk unknown
- 2005-02-02 PL PL05701307T patent/PL1711177T3/pl unknown
- 2005-02-02 AR ARP050100399A patent/AR047531A1/es not_active Application Discontinuation
- 2005-02-02 CA CA2555262A patent/CA2555262C/en not_active Expired - Fee Related
- 2005-02-02 WO PCT/EP2005/001021 patent/WO2005074922A1/en active IP Right Grant
- 2005-02-02 BR BRPI0507375-8A patent/BRPI0507375A/pt not_active IP Right Cessation
- 2005-02-02 ES ES05701307T patent/ES2307144T3/es not_active Expired - Lifetime
- 2005-02-02 SI SI200530297T patent/SI1711177T1/sl unknown
- 2005-02-02 KR KR1020067017754A patent/KR20060124734A/ko not_active Application Discontinuation
- 2005-02-02 JP JP2006551790A patent/JP4908233B2/ja not_active Expired - Fee Related
- 2005-02-02 GE GEAP20059600A patent/GEP20094633B/en unknown
- 2005-02-02 MX MXPA06008787A patent/MXPA06008787A/es active IP Right Grant
- 2005-02-02 EA EA200601418A patent/EA011032B1/ru not_active IP Right Cessation
- 2005-02-02 EP EP05701307A patent/EP1711177B1/en not_active Expired - Lifetime
- 2005-02-02 AP AP2006003701A patent/AP2006003701A0/xx unknown
- 2005-02-02 DO DO2005000014A patent/DOP2005000014A/es unknown
- 2005-02-02 AU AU2005210114A patent/AU2005210114B2/en not_active Ceased
- 2005-02-02 NZ NZ548896A patent/NZ548896A/en unknown
- 2005-02-03 UY UY28738A patent/UY28738A1/es not_active Application Discontinuation
- 2005-02-03 PA PA20058622801A patent/PA8622801A1/es unknown
- 2005-02-03 GT GT200500020A patent/GT200500020A/es unknown
- 2005-02-03 US US11/050,360 patent/US8138217B2/en not_active Expired - Fee Related
-
2006
- 2006-07-26 ZA ZA200606179A patent/ZA200606179B/xx unknown
- 2006-07-27 IL IL177141A patent/IL177141A0/en unknown
- 2006-08-03 TN TNP2006000244A patent/TNSN06244A1/fr unknown
- 2006-08-03 MA MA29227A patent/MA28429B1/fr unknown
- 2006-08-03 CR CR8546A patent/CR8546A/es not_active Application Discontinuation
- 2006-08-10 EC EC2006006767A patent/ECSP066767A/es unknown
- 2006-08-23 NO NO20063768A patent/NO20063768L/no not_active Application Discontinuation
-
2007
- 2007-06-07 HK HK07106106.1A patent/HK1101343A1/xx not_active IP Right Cessation
-
2008
- 2008-08-07 CY CY20081100834T patent/CY1108246T1/el unknown
-
2012
- 2012-02-24 US US13/404,697 patent/US8481584B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| ECSP045229A (es) | Piridinonas sustituidas como moduladores de la p38 map quinasa | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
| AR067599A1 (es) | Derivados de indazol sustituido activos como inhibidores de quinasa | |
| ECSP109953A (es) | Derivados de piridazinona | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| EA201000615A1 (ru) | Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы) | |
| ECSP109937A (es) | Pirimidil ciclopentanos como inhibidores de la proteína quinasa akt. | |
| EA201101566A1 (ru) | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| AR006906A1 (es) | Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis | |
| WO2006136837A3 (en) | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| ECSP078062A (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
| EA201000101A1 (ru) | Производные пиримидина 934 | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| AR058329A1 (es) | Derivados de pirazolo (4,3-c) piridina sustituidos activos como inhibidores de quinasa, un metodo para su preparacion y composicion farmaceutica | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| PA8589801A1 (es) | Aminoalcoxiindoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |